Clinical Trials Browser

Phase 1 × Lung Neoplasms × MRX-2843 × Clear all

NCT04762199 2025-05-09

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms